Zevra Therapeutics (NASDAQ:ZVRA) Price Target Raised to $21.00

Zevra Therapeutics (NASDAQ:ZVRA) had its target price raised by equities research analysts at Roth Mkm from $19.00 to $21.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Roth Mkm’s price objective suggests a potential upside of 177.04% from the stock’s current price.

A number of other brokerages have also recently weighed in on ZVRA. HC Wainwright lifted their price target on shares of Zevra Therapeutics from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Friday. Canaccord Genuity Group dropped their price target on Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday, September 18th. Maxim Group boosted their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday. William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 14th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Price Performance

Shares of ZVRA opened at $7.58 on Tuesday. The stock has a market cap of $317.25 million, a P/E ratio of -5.61 and a beta of 1.94. Zevra Therapeutics has a 1 year low of $3.89 and a 1 year high of $8.95. The stock’s 50-day moving average price is $7.07 and its two-hundred day moving average price is $5.72. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.80.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The firm had revenue of $4.45 million during the quarter, compared to analyst estimates of $4.08 million. Zevra Therapeutics had a negative net margin of 274.10% and a negative return on equity of 124.85%. During the same quarter in the prior year, the business earned ($0.15) earnings per share. On average, equities analysts predict that Zevra Therapeutics will post -1.58 earnings per share for the current year.

Insider Transactions at Zevra Therapeutics

In other news, Director Thomas Anderson bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The shares were acquired at an average price of $6.81 per share, with a total value of $68,100.00. Following the transaction, the director now owns 20,000 shares in the company, valued at $136,200. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 22,000 shares of company stock valued at $140,340 over the last three months. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Armistice Capital LLC bought a new stake in Zevra Therapeutics during the 4th quarter worth about $1,755,000. Sanctuary Advisors LLC acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at about $474,000. Vanguard Group Inc. raised its holdings in Zevra Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock worth $9,883,000 after acquiring an additional 58,866 shares in the last quarter. Retirement Planning Co of New England Inc. boosted its position in Zevra Therapeutics by 11.0% during the first quarter. Retirement Planning Co of New England Inc. now owns 430,193 shares of the company’s stock valued at $2,495,000 after purchasing an additional 42,766 shares during the last quarter. Finally, Mystic Asset Management Inc. grew its stake in Zevra Therapeutics by 15.4% in the first quarter. Mystic Asset Management Inc. now owns 266,297 shares of the company’s stock valued at $1,545,000 after purchasing an additional 35,514 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.